ISCT Open Access Webinars

Extending CAR-T Therapies to Hodgkin & T Cell Lymphoma 

11-23-2021 19:45

Lecture Description:

The ISCT ANZ Cell & Gene Therapy Translation Lecture Series aims to provide ISCT members innovative and ground-breaking research in cell and gene therapy. These lectures will be presented by world-leading experts and will focus on cutting edge advances in cell and gene therapy development, manufacturing, and clinical application.

In the first lecture of the series, Professor Helen Heslop will address the following topics:

- Targeting CD30 in Hodgkin lymphoma
- Targeting CD5 and CD7 in T cell lymphoma
- Allogeneic Cell Strategies

Extending CAR-T Therapies to Hodgkin and T Cell Lymphoma  

Lecture 1 of the ISCT ANZ Cell & Gene Therapy Translation Lecture Series
Organized by the ISCT Australia & New Zealand Regional Executive Committee

Co-Chaired By: 

Rajiv Khanna, PhD AO
ISCT ANZ Regional Vice-President
QIMR Berghofer Medical Research Institute

Professor Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR). He is the Coordinator of QIMR Berghofer Centre for Immunotherapy and Vaccine Development. He holds Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia and was also appointed as Honorary Professor at the University of Queensland and Griffith University, Brisbane. Professor Khanna is a Fellow of Australian Academy of Health and Medical Sciences.

Zlatibor Velickovic, PhD 
ISCT ANZ Regional Vice-President Elect
Department of Cell & Molecular Therapies
Royal Prince Alfred Hospital

Zlatibor Velickovic is the Production Manager at the Department of Cell & Molecular Therapies, Royal Prince Alfred Hospital, Sydney, Australia. He manages the GMP facility and production activities for many in-house and industry-sponsored cell and gene therapy projects and clinical trials. Zlatibor is a Research Fellow at the Faculty of Medicine and Health at the University of Sydney and the International Society for Cell & Gene Therapy (ISCT) Regional Vice-President Elect, Australia & New Zealand.


Helen Heslop, MD, DSc (Hon)
Departments of Medicine and Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
United States

Helen Heslop is Dan L Duncan Chair, Professor of Medicine and Pediatrics at Baylor College of Medicine, and the Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital. She is also the Interim Director of the Dan L. Duncan Cancer Comprehensive Center at Baylor College of Medicine. Dr Heslop is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy. She therefore has extensive experience in developing and conducting transplant studies and cell and gene therapy studies and currently serves as sponsor for over 20 Investigational New Drug applications for cell therapy products with the FDA.


1 Files

Related Entries and Links

No Related Resource entered.